A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early...
Everolimus, a once daily pill that blocks the mTOR pathway, can reduce the size of non-cancerous kidney tumours1 and is licensed today in the UK. Previously embolisation or surgery has been the only option for Tuberous Sclerosis Complex patients with kidney tumours...
More...